"The tolerability of weekly TAXOL in advanced non-small cell lung ... of malignant cell populations that are resistant to chemotherapy and may inhibit tumor regrowth between cycles," explained ...

Despite this proven effectiveness, the use of weekly paclitaxel as the standard taxane-based first-line chemotherapy regimen for patients with mBC has some limitations. The poor water solubility ...

CHICAGO, Illinois — In a result that should change clinical practice, a low-dose weekly schedule of the breast cancer chemotherapy stalwart paclitaxel appears to be less toxic than the standard ...

20%). Weekly paclitaxel after standard adjuvant chemotherapy with doxorubicin and cyclophosphamide improves disease-free and overall survival in women with breast cancer. (ClinicalTrials.gov ...

Taxol is used in combination with other chemotherapy drugs and surgery. In Australia, it is used to treat ovarian, breast, cervical, endometrial and non-small cell lung cancers.

Breast cancer patients obtained the same disease control with less toxicity when they received weekly low-dose chemotherapy with paclitaxel instead of a higher dose given every 2 weeks.

Safety and Efficacy of Using a Single Agent or a Phase II Agent Before Instituting Standard Combination Chemotherapy in Previously ... We investigated 96-hour paclitaxel infusion combined with weekly ...

In patients with recurrent platinum-resistant ovarian cancer, the addition of bevacizumab to chemotherapy (pegylated doxorubicin, topotecan, or weekly paclitaxel) prolonged progression-free ...

The phase III trial, which enrolled 2233 patients, compared two dose-dense chemotherapy regimens: Weekly nab-paclitaxel (125 mg/m 2 for eight cycles) vs biweekly solvent-based paclitaxel (175 mg/m ...

The oncogene AEG-1 shows promise as a target for managing chemotherapy-induced peripheral neuropathy, according to a recently published study.

planned delayed primary surgery). “We need to conclude 3-weekly carboplatin-paclitaxel remains the standard-of-care chemotherapy component for the majority of women undergoing of first-line ...